0000731766-23-000003.txt : 20230113 0000731766-23-000003.hdr.sgml : 20230113 20230113060114 ACCESSION NUMBER: 0000731766-23-000003 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20230113 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230113 DATE AS OF CHANGE: 20230113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNITEDHEALTH GROUP INC CENTRAL INDEX KEY: 0000731766 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 411321939 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10864 FILM NUMBER: 23527069 BUSINESS ADDRESS: STREET 1: UNITEDHEALTH GROUP CENTER STREET 2: 9900 BREN ROAD EAST CITY: MINNEAPOLIS STATE: MN ZIP: 55343 BUSINESS PHONE: 9529361300 MAIL ADDRESS: STREET 1: 9900 BREN ROAD EAST CITY: MINNETONKA STATE: MN ZIP: 55343 FORMER COMPANY: FORMER CONFORMED NAME: UNITED HEALTHCARE CORP/ DATE OF NAME CHANGE: 20000309 FORMER COMPANY: FORMER CONFORMED NAME: UNITED HEALTHCARE CORP DATE OF NAME CHANGE: 19920703 8-K 1 unh-20230113.htm 8-K unh-20230113
0000731766false00007317662023-01-132023-01-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
—————————————
FORM 8-K
—————————————
Current Report
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 13, 2023
—————————————
UNITEDHEALTH GROUP INCORPORATED
(Exact name of registrant as specified in its charter)
—————————————
Delaware1-1086441-1321939
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
UnitedHealth Group Center, 9900 Bren Road East,Minnetonka,Minnesota55343
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (952) 936-1300
N/A
(Former name or former address, if changed since last report.)
—————————————
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $.01 par valueUNHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02.    Results of Operations and Financial Condition.

On January 13, 2023, UnitedHealth Group Incorporated (the “Company”) issued a press release announcing its fourth quarter and full year 2022 results. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.
Item 9.01.    Financial Statements and Exhibits.
ExhibitDescription
104Cover Page Interactive Data File (formatted as Inline XBRL).



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 13, 2023                 
UNITEDHEALTH GROUP INCORPORATED
By: /s/ Kuai H. Leong
Kuai H. Leong
Deputy Corporate Secretary

EX-99.1 2 a2022q4exhibit991.htm EX-99.1 Document

uhglogo.jpg
UnitedHealth Group Reports 2022 Results
Revenues of $324.2 Billion Grew 13% Year-Over-Year, with Double-Digit Growth at both Optum and UnitedHealthcare
Cash Flows from Operations were $26.2 Billion or 1.3x Net Income
Full Year and Fourth Quarter Net Earnings were $21.18 and $5.03 Per Share
Full Year and Fourth Quarter Adjusted Net Earnings were $22.19 and $5.34 Per Share
MINNETONKA, Minn. (January 13, 2023) – UnitedHealth Group (NYSE: UNH) reported full year and fourth quarter 2022 results reflecting broad-based growth at Optum and UnitedHealthcare.
“We expect the efforts by the people of our company that led to strong performance in 2022 will define 2023 as well, especially delivering balanced growth enterprise-wide, improving support for consumers and care providers, and investing to make high-quality care simpler, more accessible and affordable for everyone,” said Andrew Witty, chief executive officer of UnitedHealth Group.
UnitedHealth Group affirmed the 2023 growth and performance objectives established at its November 29th Investor Conference, including revenues of $357 billion to $360 billion, net earnings of $23.15 to $23.65 per share, adjusted net earnings of $24.40 to $24.90 per share and cash flows from operations of $27 billion to $28 billion.
Page 1 of 6




uhglogo.jpg
Quarterly and Annual Financial Performance
Three Months EndedYear Ended
December 31,December 31,September 30,December 31,December 31,
20222021202220222021
Revenues$82.8 billion$73.7 billion$80.9 billion$324.2 billion$287.6 billion
Earnings from Operations$6.9 billion$5.5 billion$7.5 billion$28.4 billion$24.0 billion
Net Margin5.8%5.5%6.5%6.2%6.0%
UnitedHealth Group’s 2022 revenues grew $36.6 billion or 13% year-over-year to $324.2 billion with double digit growth at both Optum and UnitedHealthcare, driven primarily by serving more people and by serving them more comprehensively.
Full year 2022 earnings from operations were $28.4 billion, an increase of 19%, with strong contributions from Optum and UnitedHealthcare. Earnings per share grew 17% compared to last year.
The medical care ratio at 82.0% for full year 2022 and 82.8% for the fourth quarter was consistent with the company’s recent Investor Conference outlook. Days claims payable were 49.9 in the fourth quarter compared to 46.8 a year ago and 50.8 in third quarter 2022. Favorable medical reserve development was $620 million in the quarter.
The full year 2022 operating cost ratio of 14.7% compared to 14.8% in 2021, with ongoing productivity gains offset by business mix and continued investments in growth initiatives.
Cash flows from operations for the full year were $26.2 billion or 1.3-times net income. During 2022, the company returned approximately $13 billion to shareholders through dividends and share repurchases. Return on equity of 27.2% in 2022 reflected the company’s strong overall growth and efficient capital structure.
Page 2 of 6



uhclogowithr.jpg
UnitedHealthcare provides health care benefits globally, serving individuals and employers, and Medicare and Medicaid beneficiaries. UnitedHealthcare is dedicated to improving the value customers and consumers receive by improving health and wellness, enhancing the quality of care received, simplifying the health care experience and reducing the total cost of care.
Quarterly and Annual Financial Performance
Three Months EndedYear Ended
December 31,December 31,September 30,December 31,December 31,
20222021202220222021
Revenues$63.0 billion$56.4 billion$62.0 billion$249.7 billion$222.9 billion
Earnings from Operations$2.9 billion$2.1 billion$3.8 billion$14.4 billion$12.0 billion
Operating Margin4.7%3.8%6.1%5.8%5.4%
UnitedHealthcare full year revenues of $249.7 billion grew $26.8 billion or 12% year-over-year, reflecting growth in the number of people served.
Full year operating earnings were $14.4 billion compared to $12.0 billion last year, reflecting growth in people served and continued strong medical and operating cost management.
People served domestically by UnitedHealthcare grew by over 1.2 million in 2022, led by the company’s community-based and senior offerings. The number of consumers served with domestic commercial benefit offerings grew by 275,000 over the past nine months.
Page 3 of 6




optumlogoforearningsrelease.jpg
Optum’s health services businesses serve the global health care marketplace, including payers, care providers, employers, governments, life sciences companies and consumers. Using market-leading information, analytics and technology to yield clinical insights, Optum helps improve overall health system performance: optimizing care quality, reducing care costs and improving the consumer experience.
Quarterly and Annual Financial Performance
Three Months EndedYear Ended
December 31,December 31,September 30,December 31,December 31,
20222021202220222021
Revenues$47.9 billion$41.1 billion$46.6 billion$182.8 billion$155.6 billion
Earnings from Operations$4.0 billion$3.4 billion$3.7 billion$14.1 billion$12.0 billion
Operating Margin8.3%8.3%7.9%7.7%7.7%
Optum full year revenues of $182.8 billion grew $27.2 billion or 17% year-over-year, led by Optum Health, and full year operating earnings increased to $14.1 billion compared to $12.0 billion last year.
Optum Health revenue per consumer served increased by 29% in 2022, driven by growth in patients served under value-based arrangements; expansion of care delivery services, including in-home, clinic-based, ambulatory surgery, behavioral and digital; and overall increasing acuity levels of the care that can be offered.
Optum Insight’s revenue backlog increased by $7.6 billion in 2022 to $30 billion, driven by the addition of Change Healthcare and growth in comprehensive managed services. In order to speed improved system performance and experiences for patients and care providers, Optum Insight is advancing its investment initiatives.
Optum Rx revenue growth of 9% in 2022 reflects continued expansion of its pharmacy care services, adding clinical value to medications, including specialty and community-based pharmacies. Adjusted scripts grew to 1.44 billion compared to 1.37 billion last year.
Page 4 of 6



About UnitedHealth Group
UnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at www.unitedhealthgroup.com and follow @UnitedHealthGrp on Twitter.

Earnings Conference Call
As previously announced, UnitedHealth Group will discuss the company’s results, strategy and future outlook on a conference call with investors at 8:45 a.m. Eastern Time today. UnitedHealth Group will host a live webcast of this conference call from the Investor Relations page of the company’s website (www.unitedhealthgroup.com). Following the call, a webcast replay will be on the Investor Relations page and at https://uhg.com/Replay through January 27, 2023. This earnings release and the Form 8-K dated January 13, 2023, can also be accessed from the Investor Relations page of the company’s website.

Non-GAAP Financial Information
This news release presents non-GAAP financial information provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America (“GAAP”). A reconciliation of the non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release.

Forward-Looking Statements
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements which are intended to take advantage of the “safe harbor” provisions of the federal securities law. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify forward-looking statements. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. Actual results could differ materially from those that management expects, depending on the outcome of certain factors including: risks associated with public health crises, large-scale medical emergencies and pandemics; our ability to effectively estimate, price for and manage medical costs; new or changes in existing health care laws or regulations, or their
Page 5 of 6



enforcement or application; the DOJ’s legal action relating to the risk adjustment submission matter; our ability to maintain and achieve improvement in quality scores impacting revenue; reductions in revenue or delays to cash flows received under government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; failure to maintain effective and efficient information systems or if our technology products do not operate as intended; cyberattacks, other privacy/data security incidents, or our failure to comply with related regulations; failure to protect proprietary rights to our databases, software and related products; risks and uncertainties associated with our businesses providing pharmacy care services; competitive pressures, including our ability to develop and deliver innovative products to health care payers and expand access to virtual care; changes in or challenges to our public sector contract awards; failure to develop and maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; failure to attract, develop, retain, and manage the succession of key employees and executives; the impact of potential changes in tax laws and regulations (including any increase in the U.S. income tax rate applicable to corporations); failure to achieve targeted operating cost productivity improvements; increases in costs and other liabilities associated with litigation, government investigations, audits or reviews; failure to manage successfully our strategic alliances or complete or receive anticipated benefits of strategic transactions; fluctuations in foreign currency exchange rates; downgrades in our credit ratings; our investment portfolio performance; impairment of our goodwill and intangible assets; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our obligations, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or continue repurchasing shares of our common stock. This above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial condition and results of operations more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-looking statements, except as required by law.
# # #

Investor Contact:Media Contact:
Zack SopcakMatt Stearns
Senior Vice PresidentSenior Vice President
952-936-7215202-276-0085
zack.sopcak@uhg.com
matt.stearns@uhg.com
Page 6 of 6




UNITEDHEALTH GROUP
Earnings Release Schedules and Supplementary Information
Year Ended December 31, 2022
                                        
Condensed Consolidated Statements of Operations
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements of Cash Flows
Supplemental Financial Information - Businesses
Supplemental Financial Information - Business Metrics
Reconciliation of Non-GAAP Financial Measure






UNITEDHEALTH GROUP
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in millions, except per share data)
(unaudited)
Three Months Ended
December 31,
Year Ended
December 31,
2022202120222021
Revenues
Premiums$64,700$57,547$257,157$226,233
Products9,3988,96137,42434,437
Services7,8346,42227,55124,603
Investment and other income8558132,0302,324
     Total revenues82,78773,743324,162287,597
Operating costs
Medical costs53,59148,159210,842186,911
Operating costs13,00911,27247,78242,579
Cost of products sold8,3148,00033,70331,034
Depreciation and amortization9827713,4003,103
     Total operating costs75,89668,202295,727263,627
Earnings from operations6,8915,54128,43523,970
Interest expense(676)(431)(2,092)(1,660)
Earnings before income taxes6,2155,11026,34322,310
Provision for income taxes(1,307)(919)(5,704)(4,578)
Net earnings 4,9084,19120,63917,732
Earnings attributable to noncontrolling interests(147)(120)(519)(447)
Net earnings attributable to UnitedHealth Group common shareholders$4,761$4,071$20,120$17,285
Diluted earnings per share attributable to UnitedHealth Group common shareholders $5.03$4.26$21.18$18.08
Adjusted earnings per share attributable to UnitedHealth Group common shareholders (a)$5.34$4.48$22.19$19.02
Diluted weighted-average common shares outstanding947955950956
(a)See page 6 for a reconciliation of the non-GAAP measure
1


UNITEDHEALTH GROUP
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions)
(unaudited)
December 31,
2022
December 31,
2021
Assets
Cash and short-term investments$27,911$23,907
Accounts receivable, net17,68114,216
Other current assets23,47723,635
Total current assets69,06961,758
Long-term investments43,72843,114
Other long-term assets132,908107,334
Total assets$245,705$212,206
Liabilities, redeemable noncontrolling interests and equity
Medical costs payable$29,056$24,483
Short-term borrowings and current maturities of long-term debt3,1103,620
Other current liabilities57,07150,189
Total current liabilities89,23778,292
Long-term debt, less current maturities54,51342,383
Other long-term liabilities15,60815,052
Redeemable noncontrolling interests4,8971,434
Equity81,45075,045
Total liabilities, redeemable noncontrolling interests and equity$245,705$212,206

2


UNITEDHEALTH GROUP
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions)
(unaudited)
Year Ended
December 31,
20222021
Operating Activities
Net earnings$20,639$17,732
Noncash items:
Depreciation and amortization3,4003,103
Deferred income taxes and other(1,004)(814)
Share-based compensation925800
Net changes in operating assets and liabilities2,2461,522
Cash flows from operating activities26,20622,343
Investing Activities
Purchases of investments, net of sales and maturities(6,837)(1,843)
Purchases of property, equipment and capitalized software(2,802)(2,454)
Cash paid for acquisitions, net(21,458)(4,821)
Other, net2,621(1,254)
Cash flows used for investing activities(28,476)(10,372)
Financing Activities
Common share repurchases(7,000)(5,000)
Dividends paid(5,991)(5,280)
Net change in short-term borrowings and long-term debt12,5362,481
Other, net4,681344
Cash flows from (used for) financing activities4,226(7,455)
Effect of exchange rate changes on cash and cash equivalents34(62)
Increase in cash and cash equivalents1,9904,454
Cash and cash equivalents, beginning of period21,37516,921
Cash and cash equivalents, end of period$23,365$21,375
3


UNITEDHEALTH GROUP
SUPPLEMENTAL FINANCIAL INFORMATION - BUSINESSES
(in millions, except percentages)
(unaudited)
Three Months Ended
December 31,
Year Ended
December 31,
2022202120222021
Revenues
UnitedHealthcare$63,046$56,384$249,741$222,899
Optum47,86841,093182,768155,565
Eliminations(28,127)(23,734)(108,347)(90,867)
Total consolidated revenues
$82,787$73,743$324,162$287,597
Earnings from Operations
UnitedHealthcare$2,932$2,121$14,379$11,975
Optum (a)3,9593,42014,05611,995
Total consolidated earnings from operations
$6,891$5,541$28,435$23,970
Operating Margin
UnitedHealthcare4.7 %3.8 %5.8 %5.4 %
Optum8.3 %8.3 %7.7 %7.7 %
Consolidated operating margin
8.3 %7.5 %8.8 %8.3 %
Revenues
UnitedHealthcare Employer & Individual - Domestic$16,281$15,355$63,599$60,023
UnitedHealthcare Employer & Individual - Global2,1682,0538,6688,345
UnitedHealthcare Employer & Individual - Total18,44917,40872,26768,368
UnitedHealthcare Medicare & Retirement28,05124,843113,671100,552
UnitedHealthcare Community & State16,54614,13363,80353,979
Optum Health$18,446$14,550$71,174$54,065
Optum Insight4,3873,25114,58112,199
Optum Rx25,85423,84999,77391,314
Optum eliminations(819)(557)(2,760)(2,013)
(a)Earnings from operations for Optum for the three months and year ended December 31, 2022 included $1,692 and $6,032 for Optum Health; $895 and $3,588 for Optum Insight; and $1,372 and $4,436 for Optum Rx, respectively. Earnings from operations for Optum for the three months and year ended December 31, 2021 included $1,229 and $4,462 for Optum Health; $951 and $3,398 for Optum Insight; and $1,240 and $4,135 for Optum Rx, respectively.
4


UNITEDHEALTH GROUP
SUPPLEMENTAL FINANCIAL INFORMATION - BUSINESS METRICS

UNITEDHEALTHCARE CUSTOMER PROFILE
(in thousands)
People ServedDecember 31, 2022September 30, 2022December 31, 2021
Commercial - Domestic:
Risk-based8,045 8,055 7,985 
Fee-based18,640 18,500 18,595 
    Total Commercial - Domestic26,685 26,555 26,580 
Medicare Advantage7,105 7,035 6,490 
Medicaid8,170 8,005 7,655 
Medicare Supplement (Standardized)4,375 4,370 4,395 
     Total Community and Senior19,650 19,410 18,540 
     Total UnitedHealthcare - Domestic Medical46,335 45,965 45,120 
Commercial - Global5,360 5,360 5,510 
     Total UnitedHealthcare - Medical51,695 51,325 50,630 
Supplemental Data
     Medicare Part D stand-alone3,295 3,310 3,700 

OPTUM PERFORMANCE METRICS
December 31, 2022September 30, 2022December 31, 2021
Optum Health Consumers Served (in millions)102101100
Optum Insight Contract Backlog (in billions)$30.0$24.1$22.4
Optum Rx Quarterly Adjusted Scripts (in millions)370359353

Note: UnitedHealth Group served 151 million unique individuals across all businesses at December 31, 2022.
5


UNITEDHEALTH GROUP
RECONCILIATION OF NON-GAAP FINANCIAL MEASURE
(in millions, except per share data)
(unaudited)
ADJUSTED NET EARNINGS PER SHARE(a)
Three Months Ended
December 31,
Year Ended December 31,Projected Year Ended
December 31,
20222021202220212023
GAAP net earnings attributable to UnitedHealth Group common shareholders$4,761$4,071$20,120$17,285$21,700 - $22,300
Intangible amortization3962801,2921,184~1,540
Tax effect of intangible amortization(98)(68)(331)(288)~(380)
Adjusted net earnings attributable to UnitedHealth Group common shareholders$5,059$4,283$21,081$18,181$22,850 - $23,450
GAAP diluted earnings per share$5.03$4.26$21.18$18.08$23.15 - $23.65
Intangible amortization per share0.420.291.361.24~1.65
Tax effect per share of intangible amortization(0.11)(0.07)(0.35)(0.30)~(0.40)
Adjusted diluted earnings per share$5.34$4.48$22.19$19.02$24.40 - $24.90

(a)Adjusted net earnings per share is a non-GAAP financial measure. Non-GAAP financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in accordance with GAAP.
Adjusted net earnings per share excludes from the relevant GAAP metric, as applicable, intangible amortization and other items, if any, that do not relate to the Company's underlying business performance. Management believes that the use of adjusted net earnings per share provides investors and management useful information about the earnings impact of acquisition-related intangible asset amortization. As amortization fluctuates based on the size and timing of the Company’s acquisition activity, management believes this exclusion provides a more useful comparison of the Company's underlying business performance and trends from period to period. While intangible assets contribute to the Company’s revenue generation, the intangible amortization is not directly related. Therefore, the related revenues are included in adjusted earnings per share.
6
EX-101.SCH 3 unh-20230113.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 unh-20230113_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 unh-20230113_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Soliciting Material Soliciting Material Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Document Information [Line Items] Document Information [Line Items] Title of 12(b) Security Title of 12(b) Security Document Information, Document [Axis] Document Information, Document [Axis] Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Tax Identification Number Entity Tax Identification Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, City or Town Entity Address, City or Town Local Phone Number Local Phone Number Document [Domain] Document [Domain] Written Communications Written Communications Cover [Abstract] Document Type Document Type Document Information [Table] Document Information [Table] Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 6 unh-20230113_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 optumlogoforearningsrelease.jpg begin 644 optumlogoforearningsrelease.jpg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end GRAPHIC 8 uhclogowithr.jpg begin 644 uhclogowithr.jpg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end GRAPHIC 9 uhglogo.jpg begin 644 uhglogo.jpg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end XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Jan. 13, 2023
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Jan. 13, 2023
Entity Registrant Name UNITEDHEALTH GROUP INCORPORATED
Entity Incorporation, State or Country Code DE
Entity File Number 1-10864
Entity Tax Identification Number 41-1321939
Entity Address, Address Line One UnitedHealth Group Center, 9900 Bren Road East,
Entity Address, City or Town Minnetonka,
Entity Address, State or Province MN
Entity Address, Postal Zip Code 55343
City Area Code 952
Local Phone Number 936-1300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $.01 par value
Trading Symbol UNH
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0000731766
Amendment Flag false
XML 11 unh-20230113_htm.xml IDEA: XBRL DOCUMENT 0000731766 2023-01-13 2023-01-13 0000731766 false 8-K 2023-01-13 UNITEDHEALTH GROUP INCORPORATED DE 1-10864 41-1321939 UnitedHealth Group Center, 9900 Bren Road East, Minnetonka, MN 55343 952 936-1300 false false false false Common Stock, $.01 par value UNH NYSE false EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.unitedhealthgroup.com/role/Cover Cover Cover 1 false false All Reports Book All Reports unh-20230113.htm a2022q4exhibit991.htm unh-20230113.xsd unh-20230113_def.xml unh-20230113_lab.xml unh-20230113_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "unh-20230113.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "unh-20230113_def.xml" ] }, "inline": { "local": [ "unh-20230113.htm" ] }, "labelLink": { "local": [ "unh-20230113_lab.xml" ] }, "presentationLink": { "local": [ "unh-20230113_pre.xml" ] }, "schema": { "local": [ "unh-20230113.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 27, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "unh", "nsuri": "http://www.unitedhealthgroup.com/20230113", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "unh-20230113.htm", "contextRef": "ic68436fc3fe64a469170c98f1370b18b_D20230113-20230113", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://www.unitedhealthgroup.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "unh-20230113.htm", "contextRef": "ic68436fc3fe64a469170c98f1370b18b_D20230113-20230113", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards.", "label": "Document [Domain]", "terseLabel": "Document [Domain]" } } }, "localname": "DocumentDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_DocumentInformationDocumentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Document Information, Document [Axis]", "terseLabel": "Document Information, Document [Axis]" } } }, "localname": "DocumentInformationDocumentAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.unitedhealthgroup.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 18 0000731766-23-000003-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000731766-23-000003-xbrl.zip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end